These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 30402826)

  • 1. Outcomes of Neoadjuvant Chemoradiation in Patients with Gastro-esophageal Junction Adenocarcinoma: a Retrospective Cohort Study in Iran.
    Farhan F; Ghalehtaki R; Mahdavi-Seresht S; Meysamie A; Yamrali M; Farazmand B; Mohammadi N; Saraee E; Mir MR; Mir A; Lashkari M; Salarvand S; Esmati E; Samiei F
    J Gastrointest Cancer; 2019 Dec; 50(4):907-912. PubMed ID: 30402826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor downstaging after neoadjuvant chemotherapy determines survival after surgery for gastric adenocarcinoma.
    Levenson G; Voron T; Paye F; Balladur P; Debove C; Chafai N; De Dios AG; Lefevre JH; Parc Y
    Surgery; 2021 Dec; 170(6):1711-1717. PubMed ID: 34561115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of repeat staging laparoscopy in locoregionally advanced gastric or gastroesophageal cancer after neoadjuvant therapy.
    Cardona K; Zhou Q; Gönen M; Shah MA; Strong VE; Brennan MF; Coit DG
    Ann Surg Oncol; 2013 Feb; 20(2):548-54. PubMed ID: 22941159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemoradiotherapy in non-cardia gastric cancer patients--does it improve survival?
    Saedi HS; Mansour-Ghanaei F; Joukar F; Shafaghi A; Shahidsales S; Atrkar-Roushan Z
    Asian Pac J Cancer Prev; 2014; 15(20):8667-71. PubMed ID: 25374187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of neoadjuvant therapy on outcomes in patients with resectable carcinoma of esophagus and gastro-esophageal junction from a tertiary cancer care center in India.
    Rao T S; Raju KVVN; Patnaik SC; Reddy P; Saksena AR; Rajappa S; Mallavarapu KM; Santa A; Gudipudi D; Boleneni N; Usofi Z; Gujjuru S; Smith L; Are C; Nusrath S
    J Surg Oncol; 2021 Jun; 123(7):1547-1557. PubMed ID: 33650697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry.
    Münch S; Habermehl D; Agha A; Belka C; Combs SE; Eckel R; Friess H; Gerbes A; Nüssler NC; Schepp W; Schmid RM; Schmitt W; Schubert-Fritschle G; Weber B; Werner J; Engel J
    Strahlenther Onkol; 2018 Feb; 194(2):125-135. PubMed ID: 29071366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mediastinal Nodal Involvement After Neoadjuvant Chemoradiation for Siewert II/III Adenocarcinoma.
    Mitchell KG; Ikoma N; Nelson DB; Maru DM; Erasmus JJ; Weston BR; Vaporciyan AA; Antonoff MB; Mehran RJ; Rice DC; Roth JA; Swisher SG; Sepesi B; Walsh GL; Correa AM; Das P; Blum MA; Badgwell BD; Hofstetter WL
    Ann Thorac Surg; 2019 Sep; 108(3):845-851. PubMed ID: 31102632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Extent of radical surgery in cardia carcinoma--esophagectomy or gastrectomy?].
    Hölscher AH; Bollschweiler E; Beckurts KT; Siewert JR
    Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():169-72. PubMed ID: 9101821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CARDIA-trial protocol: a multinational, prospective, randomized, clinical trial comparing transthoracic esophagectomy with transhiatal extended gastrectomy in adenocarcinoma of the gastroesophageal junction (GEJ) type II.
    Leers JM; Knepper L; van der Veen A; Schröder W; Fuchs H; Schiller P; Hellmich M; Zettelmeyer U; Brosens LAA; Quaas A; Ruurda JP; van Hillegersberg R; Bruns CJ
    BMC Cancer; 2020 Aug; 20(1):781. PubMed ID: 32819399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant Radiochemotherapy for Patients with Locally Advanced Esophagogastric Junction Adenocarcinoma.
    Marica CD; Birlă R; Marica R; Panaitescu E; Constantinoiu S
    Chirurgia (Bucur); 2018; 113(2):192-201. PubMed ID: 29733013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Esophagectomy Timing After Neoadjuvant Therapy for Distal Esophageal Adenocarcinoma.
    Franko J; Voynov G; Goldman CD
    Ann Thorac Surg; 2016 Mar; 101(3):1123-30. PubMed ID: 26652139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognosis after neoadjuvant chemoradiation or chemotherapy for locally advanced gastro-oesophageal junctional adenocarcinoma.
    Vos EL; Carr RA; Hsu M; Nakauchi M; Nobel T; Russo A; Barbetta A; Tan KS; Tang L; Ilson D; Ku GY; Wu AJ; Janjigian YY; Yoon SS; Bains MS; Jones DR; Coit D; Molena D; Strong VE
    Br J Surg; 2021 Nov; 108(11):1332-1340. PubMed ID: 34476473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma.
    Anderegg MCJ; van der Sluis PC; Ruurda JP; Gisbertz SS; Hulshof MCCM; van Vulpen M; Mohammed NH; van Laarhoven HWM; Wiezer MJ; Los M; van Berge Henegouwen MI; van Hillegersberg R
    Ann Surg Oncol; 2017 Aug; 24(8):2282-2290. PubMed ID: 28424936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term survival based on pathologic response to neoadjuvant therapy in esophageal cancer.
    Tiesi G; Park W; Gunder M; Rubio G; Berger M; Ardalan B; Livingstone A; Franceschi D
    J Surg Res; 2017 Aug; 216():65-72. PubMed ID: 28807215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours.
    Thomaschewski M; Hummel R; Petrova E; Knief J; Wellner UF; Keck T; Bausch D
    World J Gastroenterol; 2018 Apr; 24(13):1429-1439. PubMed ID: 29632424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant chemoradiotherapy improves survival in locally advanced adenocarcinoma of esophagogastric junction compared with neoadjuvant chemotherapy: a propensity score matching analysis.
    Li J; Zhao Q; Ge X; Song Y; Tian Y; Wang S; Liu M; Qiao X
    BMC Surg; 2021 Mar; 21(1):137. PubMed ID: 33731072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction.
    Moehler M; Gockel I; Roessler HP; Arnold D; Trarbach T; Thomaidis T; Klautke G; Rödel C; Brenner B; Lang H; Galle PR; Schimanski CC; Schmidberger H
    BMC Cancer; 2013 Feb; 13():75. PubMed ID: 23394629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between Clinically Staged Node-Negative Esophageal Adenocarcinoma and Overall Survival Benefit From Neoadjuvant Chemoradiation.
    Gabriel E; Attwood K; Du W; Tuttle R; Alnaji RM; Nurkin S; Malhotra U; Hochwald SN; Kukar M
    JAMA Surg; 2016 Mar; 151(3):234-45. PubMed ID: 26559488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Staging of adenocarcinoma of the gastroesophageal junction.
    Parry K; Haverkamp L; Bruijnen RC; Siersema PD; Offerhaus GJ; Ruurda JP; van Hillegersberg R
    Eur J Surg Oncol; 2016 Mar; 42(3):400-6. PubMed ID: 26777127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relevance of the Siewert classification in the era of multimodal therapy for adenocarcinoma of the gastro-oesophageal junction.
    Curtis NJ; Noble F; Bailey IS; Kelly JJ; Byrne JP; Underwood TJ
    J Surg Oncol; 2014 Mar; 109(3):202-7. PubMed ID: 24243140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.